ScreenerHero

FLNA Filana Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · filanatx.com
0.8157USD-6.77%Mkt Cap: 39.40M $P/E: —

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical t…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap39.40M USD
Enterprise Value-40.42M USD
Revenue (TTM)—
Gross Profit-15.65M USD
Net Income (TTM)-90.97M USD
Revenue/Share—
Last Price0.8157 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees17
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG1.62
EV/EBITDA3.19
EV/Revenue—
P/S—
P/B0.66
EPS (TTM)-0.87
EPS (Forward)—
52W Range
0.67003% of range4.980
52W High4.980 USD
52W Low0.6700 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-122.27%
ROA-76.86%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-32.25M USD
CapEx (TTM)581.00K USD
FCF Margin—
FCF Yield10.09%
Net Debt-82.68M USD
Net Debt/EBITDA6.52
Balance Sheet
Debt/Equity—
Current Ratio2.08
Quick Ratio2.06
Book Value/Sh1.32 USD
Cash/Share1.71 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateDec 13, 2012
Pay Date—
Splits
Last Split1:7
Split DateMay 10, 2017
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)6.500 USD
Upside (mean)+696.9%
Target Range5.000 USD – 8.000 USD
5.000+696.9% to mean8.000
# Analysts2
Ownership
Shares Out.48.31M
Float46.92M
Insiders2.05%
Institutions26.81%
Short Interest
Short Ratio23.7d
Short % Float13.14%
Short % Out.12.87%
Shares Short6.22M
Short (prev mo.)6.31M
Technical
SMA 500.8836 (-7.7%)
SMA 2001.490 (-45.3%)
Beta-0.66
S&P 52W Chg16.45%
Avg Vol (30d)3.92M
Avg Vol (10d)1.88M
Technical Indicators
RSI (14)46.2
MACD-0.0057
MACD Signal-0.0153
MACD Hist.+0.0096
BB Upper1.011 USD
BB Middle0.8297 USD
BB Lower0.6487 USD
BB Width43.63%
ATR (14)0.0993 USD
Vol Ratio (20d)0.13x